



February 14, 2025

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Integrated Filing (Financials) for the quarter and nine months ended December 31, 2024

With reference to the captioned subject and pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we Zota Health Care Limited (“the Company”) are submitting herewith the enclosed Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat

Encl: a/a

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Zota Health Care Limited

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Zota Health Care Limited** (the "Company") for the quarter and nine months ended **December 31, 2024** ("the Statement") attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Management's Responsibility

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing

PRADEEP K SINGHI & ASSOCIATES

CHARTERED ACCOUNTANTS

Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 13/02/2025

Place: Surat

For Pradeep K. Singhi & Associates

Chartered Accountants

FRN : 0126027W

**PRADEEP
KUMAR
SINGHI**

Digitally signed by
PRADEEP KUMAR
SINGHI
Date: 2025.02.13
18:56:45 +05'30'

Pradeep Kumar Singhi

(Partner)

UDIN: 25024612BMONHY3287

Unaudited Standalone Financial Results for the Quarter and Nine Months ended 31st December, 2024

(Amount ₹ in Lakhs, except per share data)

Particulars	Quarter Ended			Nine months ended		Year Ended
	31-12-2024 (Unaudited)	30-09-2024 (Unaudited)	31-12-2023 (Unaudited)	31-12-2024 (Unaudited)	31-12-2023 (Unaudited)	31-03-2024 (Audited)
I. Revenue from Operations	6813.08	5900.92	4283.46	17934.36	11923.54	16658.50
II. Other Income	168.91	97.01	37.76	312.81	135.81	205.19
III. Total Income	6981.99	5997.93	4321.22	18247.17	12059.35	16863.69
IV. Expenses:						
Cost of Materials Consumed	303.90	430.72	400.53	1013.73	983.71	1277.46
Purchases of Stock-in-Trade	4699.98	2907.89	2355.30	9952.55	5954.96	9520.35
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(943.99)	215.20	(41.09)	(168.56)	701.98	(352.67)
Employee Benefit Expenses	854.97	729.09	528.42	2228.23	1384.24	1997.36
Finance Costs	3.83	51.91	0.43	97.66	30.05	36.47
Depreciation / Amortisation and Depletion Expense	81.75	73.35	83.11	222.74	214.87	300.73
Other Expenses	1767.41	1293.73	827.58	4158.43	2314.55	3593.37
Total Expenses	6767.84	5701.91	4154.27	17504.78	11584.36	16373.07
V. Profit before Exceptional items and tax from continuing operations (III-IV)	214.15	296.02	166.94	742.38	474.99	490.61
VI. Exceptional Items	-	-	-	-	-	-
VII. Profit/(loss) before tax	214.15	296.02	166.94	742.38	474.99	490.61
VIII. Tax Expense:						
(1) Current tax	(15.23)	84.74	50.59	134.22	139.05	153.08
(1.1) I.T. & DD Tax Provision Created Short/ excess	(2.49)	-	(6.28)	(2.49)	(6.28)	(6.28)
(2) Deferred Tax	(24.10)	23.91	(6.94)	(9.26)	(26.56)	(5.82)
IX. Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	207.77	235.19	115.68	601.39	315.66	337.99
X. Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-
XI. Tax Expense of discontinued Operations	-	-	-	-	-	-
XII. Profit/ (Loss) from Discontinued Operations (after Tax) (X-XI)	-	-	-	-	-	-
XIII. Profit/ (Loss) for the period	207.77	235.19	115.68	601.39	315.66	337.99
XIV. Other Comprehensive Income						
A (i) Items that will not be reclassified to Statement of profit and loss	22.94	(20.58)	(10.31)	12.98	15.93	19.82
(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(5.77)	5.18	2.59	(3.27)	(4.01)	(4.99)
B (i) Items that will be reclassified to Statement of profit and loss	-	-	-	-	-	-
(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-	-	-	-	-
Other comprehensive income for the period, net of tax	17.17	(15.40)	(7.71)	9.71	11.92	14.83
Total comprehensive income for the period (XIII + XIV)	224.94	219.79	107.97	611.10	327.59	352.82
Paid-up Equity Share Capital	2757.10	2740.76	2584.73	2757.10	2584.73	2584.73
Other Equity	-	-	-	-	-	9592.80
Earnings per equity share of face value of ₹ 10 each						
(1) Basic (in ₹)	0.76	0.89	0.45	2.23	1.23	1.32
(2) Diluted (in ₹)	0.70	0.82	0.44	2.07	1.21	1.29

* denotes figures less than a lakh

For and on behalf of the Board



(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)


Company Secretary
Ashvin Variya
Date: 13-02-2025
Place : Surat


Chief Financial Officer
Viral Mandviwala



For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W


PRADEEP
KUMAR
SINGHI
Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com
CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Zota Health Care Limited

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Zota Health Care Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the **quarter and nine months ended December 31, 2024** ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Management's Responsibility

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

- a. Zota Health Care Limited (Parent)
- b. Zota Healthcare Lanka (Pvt.) Ltd. (Wholly Owned Subsidiary)

PRADEEP K SINGHI & ASSOCIATES

CHARTERED ACCOUNTANTS

- c. Davaindia Health Mart Limited (Wholly Owned Subsidiary)
- d. Zota Nex Tech Limited (Wholly Owned Subsidiary)
- e. Everyday Herbal Beauty Care Private Limited (Subsidiary)
- f. Everyday Herbal Beauty And Wellness Care Private Limited (Subsidiary)

Conclusion

Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

We did not review the interim financial statements of the subsidiaries included in the consolidated unaudited financial results that reflect total revenues of Rs. 3367.82 Lakhs and Rs.7951.52 Lakhs, total net profit/(loss) after tax of Rs. (1896.76) Lakhs and Rs. (4593.72) Lakhs and total comprehensive income of Rs. (1887.83) Lakhs and Rs. (4585.21) Lakhs, respectively for the quarter and nine months ended December 31, 2024, as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

Date: 13/02/2025

Place: Surat

**For Pradeep K. Singhi & Associates
Chartered Accountants**

FRN : 0126027W

**PRADEEP
KUMAR
SINGHI**

Digitally signed by
PRADEEP KUMAR
SINGHI
Date: 2025.02.13
18:57:51 +05'30'

**Pradeep Kumar Singhi
(Partner)**

UDIN: 25024612BMONHZ7791

Particulars	Quarter Ended			Nine months ended		Year Ended
	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I. Revenue from Operations	7212.38	6727.58	4693.14	19570.03	13085.28	18048.85
II. Other Income	50.59	54.27	15.14	106.65	69.93	115.61
III. Total Income	7262.97	6781.86	4708.28	19676.68	13155.21	18164.46
IV. Expenses:						
Cost of Materials Consumed	303.90	430.72	400.53	1013.73	983.71	1277.46
Purchases of Stock-in-Trade	4808.81	2905.91	2355.30	10036.34	5954.96	9520.35
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(1929.48)	(211.11)	(218.55)	(2107.23)	452.27	(1127.79)
Employee Benefit Expenses	2381.99	2006.36	775.77	6012.99	1833.67	3045.05
Finance Costs	157.40	285.33	113.87	732.54	310.72	478.82
Depreciation / Amortisation and Depletion Expense	1134.53	951.23	507.92	2888.11	1328.63	2008.51
Other Expenses	2254.22	1682.72	1046.78	5434.14	2956.74	4578.35
Total Expenses	9111.37	8051.15	4981.63	24010.62	13820.70	19780.75
V. Profit before Exceptional items and tax from continuing operations (III-IV)	(1848.40)	(1269.30)	(273.35)	(4333.94)	(665.49)	(1616.29)
VI. Exceptional Items	-	-	-	-	-	-
VII. Profit/(loss) before tax	(1848.40)	(1269.30)	(273.35)	(4333.94)	(665.49)	(1616.29)
VIII. Tax Expense:						
(1) Current tax	(15.23)	84.74	50.59	134.22	139.05	153.08
(1.1) I.T. & DD Tax Provision Created Short/ excess	(2.49)	-	(6.28)	(2.49)	(6.28)	(6.28)
(2) Deferred Tax	(63.86)	135.94	23.83	80.65	55.24	328.31
IX. Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	(1894.54)	(1218.10)	(293.84)	(4385.02)	(743.02)	(1434.79)
X. Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-
XI. Tax Expense of discontinued Operations	-	-	-	-	-	-
XII. Profit/ (Loss) from Discontinued Operations (after Tax) (X-XI)	-	-	-	-	-	-
XIII. Profit/ (Loss) for the period	(1894.54)	(1218.10)	(293.84)	(4385.02)	(743.02)	(1434.79)
XIV. Other Comprehensive Income						
A (i) Items that will not be reclassified to Statement of profit and loss	34.81	(22.78)	(10.64)	24.41	16.51	24.59
(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(8.74)	5.73	2.68	(6.13)	(4.15)	(6.18)
B (i) Items that will be reclassified to Statement of profit and loss	0.03	(0.01)	*	(0.04)	(0.03)	(0.07)
(ii) Income Tax relating to items that will be reclassified to profit and loss	*	*	*	*	*	0.02
Other comprehensive income for the period, net of tax	26.09	(17.06)	(7.97)	18.26	12.33	18.36
Total comprehensive income for the period (XIII + XIV)	(1868.45)	(1235.16)	(301.80)	(4366.77)	(730.69)	(1416.42)
Profit attributable to:						
Owners of the parent	(1868.17)	(1210.24)	(293.84)	(4350.80)	(743.02)	(1434.79)
Non-controlling interest	(26.37)	(7.86)	-	(34.23)	-	-
Other comprehensive income attributable to:						
Owners of the parent	26.09	(17.06)	(7.97)	18.26	12.33	18.36
Non-controlling interest	-	-	-	-	-	-
Total Comprehensive Income attributable to:						
Owners of the parent	(1842.08)	(1227.30)	(301.80)	(4332.54)	(730.69)	(1416.42)
Non-controlling interest	(26.37)	(7.86)	-	(34.23)	-	-
Paid-up Equity Share Capital	2757.10	2740.76	2584.73	2757.10	2584.73	2584.73
Other Equity						6412.92
Earnings per equity share of face value of ₹ 10 each						
(1) Basic (in ₹)	(6.80)	(4.57)	(1.14)	(16.12)	(2.90)	(5.59)
(2) Diluted (in ₹)	(6.31)	(4.23)	(1.11)	(14.96)	(2.84)	(5.47)

* denotes figures less than a lakh
For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)


Company Secretary
Ashvin Variya
Date: 13-02-2025
Place : Surat


Chief Financial Officer
Viral Mandviwala



For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W
Digitally signed by
PRADEEP KUMAR
SINGHI
Date: 2025.02.13
18:58:22 +05'30'
Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/396, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com
CIN : L24231GJ2000PLCO38352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Notes:

1. The above financial results for the quarter and nine months ended December 31, 2024 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on February 13, 2025.
2. The financial results have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with (Indian Accounting Standards) rules, 2015, as amended.
3. The Statutory Auditors have carried out Limited Review of the financial results for the quarter and nine months ended December 31, 2024.
4. During the quarter; upon receipt of balance 75% amount i.e. Rs. 381.75/- per warrant of the warrants issue price, the Board of Directors of the Company has on December 04, 2024 allotted 1,63,425 equity shares upon conversion of warrants to 17 Warrant Holders.
5. The company has evaluated its Operating segment in accordance with Ind As 108 and has concluded that it is engaged in a single operating segment.
6. The consolidated results include the result of following companies:
 - A) Wholly owned subsidiaries:
 - i) Zota Healthcare Lanka (Pvt) Ltd
 - ii) Davaindia Health Mart Limited
 - iii) Zota Nex Tech Limited
 - B) Subsidiaries:
 - i) Everyday Herbal Beauty Care Private Limited
 - ii) Everyday Herbal Beauty And Wellness Care Private Limited
7. In the consolidated financial results, the Company has adopted Ind As 116 'Leases' and applied the Standard to its leases. This has resulted in recognizing a Right-of-Use Asset of Rs. 10503.66 lakhs and a corresponding Lease Liability of Rs. 11530.73 lakhs as at December 31, 2024. The impact of this on the consolidated profit for the quarter and nine months ended December 31, 2024 is Rs. 138.77 lakhs and Rs. 453.69 lakhs respectively.
8. Figures pertaining to the previous period have been regrouped/rearranged, reclassified and restated wherever considered necessary, to make them comparable with those of current period.



Registered Office :

Zota House, 2/396, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com
CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

B. Statement of Deviation / Variation in utilisation of funds raised							(Rs. in lakhs)
Name of listed entity		ZOTA HEALTH CARE LIMITED					
Mode of Fund Raising		Preferential Issue					
Date of Raising Funds		(1) August 14, 2024 (2) December 04, 2024					
Amount Raised		(1) Rs. 4445.07 lakh comprising of Rs. 509/- per equity shares received on allotment of equity shares. This has been raised on August 14, 2024. (2) Rs. 3365.55/- lakh upfront money comprising of Rs. 127.25/- (i.e 25% of Warrant Issue Price Rs. 509/-) per convertible Warrant received on subscription and allotment of convertible warrants. This has been raised on August 14, 2024. (3) Rs. 623.87 lakh (being 75% of warrant Issue Price i.e Rs. 381.75/- each) per fully convertible warrants received on conversion of 1,63,425 fully convertible warrants into equivalent number of equity shares. This has been raised on December 04, 2024.					
Report filed for Quarter ended		December 31, 2024					
Monitoring Agency		Applicable					
Monitoring Agency Name, if applicable		CRISIL Ratings Limited					
Is there a Deviation / Variation in use of funds raised		No					
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders		Not Applicable					
If Yes, Date of shareholder Approval		Not Applicable					
Explanation for the Deviation / Variation		Not Applicable					
Comments of the Audit Committee after review		The Committee has noted that there is no deviation/ variation.					
Comments of the auditors, if any		No comments					
Objects for which funds have been raised and where there has been a deviation, in the following table							
Original Object	Modified Object, if any	Original Allocation (Refer Note 1)	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if Any	
Expansion of DAVAINDIA Project	Not Applicable	14325.83	Not Applicable	4920.62	Not Applicable	Not Applicable	
Working capital requirement	Not Applicable	2686.09	Not Applicable	1918.87	Not Applicable		
General Corporate Purpose	Not Applicable	895.36	Not Applicable	95.00	Not Applicable		

Note 1: Out of the issue proceeds of Rs 179.07 crore, the Company has received issue proceeds of Rs 84.34 crores till the quarter ended December 31, 2024. Further, the balance amount Rs 94.73 crore is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 (eighteen) months from the date of allotment of the Warrants i.e. February 13, 2026, as per the Notice to Shareholders dated July 13, 2024.

For Zota Health Care Limited

ASHVIN
BHAGAVANBHAI VARIYA
AI VARIYA
Digitally signed by
ASHVIN
BHAGAVANBHAI VARIYA
Date: 2025.02.13
19:48:13 +05'30'

Ashvin Variya
(Company Secretary & Compliance Officer)

Date: 13.02.2025

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES – Not Applicable, during the quarter, the Company has not made any default on repayment of Loan. Further, the Company has not issued any Debt Securities till date.

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) – Not Applicable

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (standalone and consolidated separately) (applicable only for annual filing i.e., 4th quarter) – Not Applicable